Boston, MA 03\/12\/2014 (wallstreetpr) – TG Therapeutics, Inc. (NASDAQ:TGTX)<\/b> is a bio-pharmaceutical company concerned with the development, commercialization and even acquisition of products geared toward treatment of cancers and diseases with unmet needs for patients. This stock has been in an exciting position since releasing its financial results last week and announcing common stock sale to a single institutional investor.<\/p>\n
Shares of the company were seen changing hands at $7.24 per share, with a gain of 7.90 percent in the early afternoon. Earlier on, the shares had touched a new 52-high level at $7.85.<\/p>\n
Clearly, investors are convinced that the management of this biopharma is acting in their best interest and they are not missing opportunity to send up the stock.<\/p>\n
Common stock offer and what it means<\/b><\/p>\n
TG Therapeutics, Inc. (NASDAQ:TGTX) announce Tuesday that it was selling about 2.7 million share of its common stock to an intuitional investor. Each share in this underwritten sale will be sold at $6.71 which reflects the closing price on Monday. The stock will be sold to Global Healthcare Fund which is a business owned by JP Morgan Asset Management.\u00a0 Approximately $18.1 million is expected to be raised from the transaction.<\/p>\n
TG Therapeutics, Inc. (NASDAQ:TGTX) hopes that the proceeds will help it towards undertaking clinical development of its leading candidate drugs TG-1101 and TGR-1202. The portion of the money will also find its way in other corporate spending.<\/p>\n
The management of TG Therapeutics, Inc. (NASDAQ:TGTX) is exciting about this offering opportunity. First because it means the company will get the money it needs to meets its plans for this year and second is that the investment comes from a premier biotechnology investor. Of course, that goes a long way to show that the company\u2019s efforts are appreciated by high-profile investors.<\/p>\n
Most recent earnings recap<\/b><\/p>\n
TG Therapeutics, Inc. (NASDAQ:TGTX) announced last week that it ended fiscal 2013 with cash and cash equivalents worth $45.4 million. That was better than $16.5 million that was there at the end of 2012. Although the company ended up with a loss in full-year 2013, the loss was narrowed from what was there in 2012. The same performance of narrowing loss was noted in the fourth quarter.<\/p>\n
2014 Outlook<\/b><\/p>\n
In the current year, TG Therapeutics, Inc. (NASDAQ:TGTX) hopes that it will move closer to brining new products to the market. Thus, the company is concerned about further studies for TG-1101 and TGR-1202 in the current year.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 03\/12\/2014 (wallstreetpr) – TG Therapeutics, Inc. (NASDAQ:TGTX) is a bio-pharmaceutical company concerned with the development, commercialization and even acquisition of products geared toward […]<\/p>\n","protected":false},"author":12,"featured_media":17177,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5124,5123,5122,5121],"stock_ticker":[],"class_list":["post-17176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-tgtx","tag-nasdaqtgtx","tag-tg-therapeutics-inc","tag-tg-therapeutics-inc-nasdaqtgtx","entry"],"acf":[],"yoast_head":"\n